EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program

Gary R Lichtenstein iD, Jessica R Allegretti iD, Edward V Loftus, Peter M Irving, Rupa Banerjee, Aline Charabaty, Tanja Kuehbacher, Eustratios Bananis, John C Woolcott, Alexis B Dalam, Krisztina Lazin, Michael Keating und 2 weitere

Inflammatory Bowel Diseases · 01.09.2025 · 31 (9) · 2352-2362

DOI: 10.1093/ibd/izae308 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.04.2025. Verfasst von Gary R Lichtenstein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program.

Methods

Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints.

Results

Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age.

Conclusions

The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age. ClinicalTrials.gov NCT03945188; NCT03996369.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansAdultMaleMiddle AgedFemaleAge FactorsDouble-Blind MethodTreatment OutcomeAgedYoung AdultFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

ageetrasimodulcerative colitis

Autor:innen und Institutionen

  • Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
  • IBD Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
  • Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Washington, DC, USA.

ORCID-Profile: Gary R Lichtenstein, Jessica R Allegretti, Silvio Danese

Förderung

  • Pfizer

Zitieren

APA

Lichtenstein, G. R., Allegretti, J. R., Loftus, E. V., Irving, P. M., Banerjee, R., Charabaty, A., Kuehbacher, T., Bananis, E., Woolcott, J. C., Dalam, A. B., Lazin, K., Keating, M., McDonnell, A., & Danese, S. (2025). Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases, 31(9), 2352-2362. https://doi.org/10.1093/ibd/izae308

Vancouver

Lichtenstein GR, Allegretti JR, Loftus EV, Irving PM, Banerjee R, Charabaty A, et al. Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 2025;31(9):2352-2362. doi:10.1093/ibd/izae308

BibTeX
@article{Lichtenstein2025,
  author = {Lichtenstein, Gary R and Allegretti, Jessica R and Loftus, Edward V and Irving, Peter M and Banerjee, Rupa and Charabaty, Aline and Kuehbacher, Tanja and Bananis, Eustratios and Woolcott, John C and Dalam, Alexis B and Lazin, Krisztina and Keating, Michael and McDonnell, Aoibhinn and Danese, Silvio},
  title = {Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {9},
  pages = {2352--2362},
  doi = {10.1093/ibd/izae308}
}
Kostenlos starten →